Topics:

IDDS Reduces Pain and Toxicity in Cancer Pain Patients

IDDS Reduces Pain and Toxicity in Cancer Pain Patients

ORLANDO—Randomized
clinical trial data presented at the 38th Annual Meeting of the American
Society of Clinical Oncology (abstract 1436) show that pain control medications
delivered through an implantable intrathecal drug delivery system (IDDS) are
significantly more effective than similar drugs given as oral or injectable
formulations.

Lead investigator Thomas J. Smith, MD, who presented the
study as a poster at the meeting, told ONI: "Oncologists should start
thinking about intrathecal drug delivery systems any time cancer patients have
severe pain. Compared to comprehensive medical management, we found that the
IDDS reduced pain scores by 52% and reduced drug side effects by one third."
The improvement in drug-related side effects was particularly apparent in
regard to fatigue and to problems with consciousness, he said.

"In this open-label, randomized study, patients treated with
IDDS plus comprehensive medical management had about 2.5 months more
good-quality life at the end of life than similar patients on comprehensive
medical management alone," said Dr. Smith, chairman of the Division of
Hematology/Oncology, Medical College of Virginia Hospitals, Richmond.

This trial included 99 patients randomized to comprehensive
medical management (CMM) and 101 patients randomized to CMM plus IDDS. About
60% of patients in each group had mixed neuropathic and nociceptive pain.
Baseline morphine oral equivalent doses were 280 mg/d in the CMM group and 260
mg/d in the IDDS group.

Baseline visual analog scale (VAS) score was 7.59 in the CMM
group and 7.44 in the IDDS group. The trial included patients with lung,
breast, prostate, colon, and pancreatic cancers. Crossover was allowed for VAS
pain scores greater than 5 and for side effects. Patients were assessed at
baseline, 2, 4, 6, 8, 10, and 12 weeks, then monthly for 6 months. Intrathecal
therapy was delivered with the Medtronic SynchroMed EL Infusion
System.

The study was powered to detect a greater than 20%
improvement in VAS pain score and/or in National Cancer Institute (NCI) Common
Toxicity Criteria score. Clinical success was defined as either a 20%
improvement in VAS pain score with equal or reduced toxicity, or a 20%
improvement in toxicity with equal or reduced VAS pain score.

Study Results

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.